

SENATE BILL No. 151

By Committee on Judiciary

2-3

1 AN ACT concerning non-intoxicating cannabinoid medicine; eliminating
2 criminal and professional penalties for recommending, dispensing,
3 distributing or possessing non-intoxicating cannabinoid medicines and
4 related paraphernalia; amending K.S.A. 2016 Supp. 21-5706, 21-5708,
5 21-5709, 65-1626 and 65-4123 and repealing the existing sections.
6

7 *Be it enacted by the Legislature of the State of Kansas:*

8 New Section 1. (a) Notwithstanding any other provision of law, a
9 person shall not be subject to arrest, prosecution or penalty in any manner
10 for possessing, utilizing, dispensing or distributing any non-intoxicating
11 cannabinoid medicine or any apparatus or paraphernalia used to administer
12 such medicine pursuant to a physician recommendation.

13 (b) This section shall be part of and supplemental to article 57 of
14 chapter 21 of the Kansas Statutes Annotated, and amendments thereto.

15 New Sec. 2. (a) Notwithstanding any other provision of law, a
16 physician shall not be subject to arrest, prosecution or penalty in any
17 manner, including any form of professional discipline by the state board of
18 healing arts, for issuing a recommendation order, with the same intent,
19 force and effect as a prescription order, to a patient for the use of non-
20 intoxicating cannabinoid medicine.

21 (b) This section shall be part of and supplemental to the Kansas
22 healing arts act.

23 New Sec. 3. (a) Notwithstanding any other provision of law, a
24 licensed pharmacist shall not be subject to arrest, prosecution or penalty in
25 any manner, including any form of professional discipline by the state
26 board of pharmacy, for dispensing or distributing any non-intoxicating
27 cannabinoid medicine pursuant to a physician recommendation order.

28 (b) This section shall be part of and supplemental to the pharmacy act
29 of the state of Kansas.

30 Sec. 4. K.S.A. 2016 Supp. 21-5706 is hereby amended to read as
31 follows: 21-5706. (a) It shall be unlawful for any person to possess any
32 opiates, opium or narcotic drugs, or any stimulant designated in K.S.A. 65-
33 4107(d)(1), (d)(3) or (f)(1), and amendments thereto, or a controlled
34 substance analog thereof.

35 (b) It shall be unlawful for any person to possess any of the following
36 controlled substances or controlled substance analogs thereof:

1 (1) Any depressant designated in K.S.A. 65-4105(e), K.S.A. 65-
2 4107(e), K.S.A. 65-4109(b) or (c) or K.S.A. 65-4111(b), and amendments
3 thereto;

4 (2) any stimulant designated in K.S.A. 65-4105(f), K.S.A. 65-4107(d)
5 (2), (d)(4), (d)(5) or (f)(2) or K.S.A. 65-4109(e), and amendments thereto;

6 (3) any hallucinogenic drug designated in K.S.A. 65-4105(d), K.S.A.
7 65-4107(g) or K.S.A. 65-4109(g), and amendments thereto, *except that it*
8 *shall not be unlawful for a person to possess non-intoxicating cannabinoid*
9 *medicine pursuant to a physician order*;

10 (4) any substance designated in K.S.A. 65-4105(g) and K.S.A. 65-
11 4111(c), (d), (e), (f) or (g), and amendments thereto;

12 (5) any anabolic steroids as defined in K.S.A. 65-4109(f), and
13 amendments thereto;

14 (6) any substance designated in K.S.A. 65-4113, and amendments
15 thereto; or

16 (7) any substance designated in K.S.A. 65-4105(h), and amendments
17 thereto, *except that it shall not be unlawful for a person to possess non-*
18 *intoxicating cannabinoid medicine pursuant to a physician*
19 *recommendation order*.

20 (c) (1) Violation of subsection (a) is a drug severity level 5 felony.

21 (2) Except as provided in subsection (c)(3):

22 (A) Violation of subsection (b) is a class A nonperson misdemeanor,
23 except as provided in subsection (c)(2)(B); and

24 (B) violation of subsection (b)(1) through (b)(5) or (b)(7) is a drug
25 severity level 5 felony if that person has a prior conviction under such
26 subsection, under K.S.A. 65-4162, prior to its repeal, under a substantially
27 similar offense from another jurisdiction, or under any city ordinance or
28 county resolution for a substantially similar offense if the substance
29 involved was 3, 4-methylenedioxymethamphetamine (MDMA), marijuana
30 as designated in K.S.A. 65-4105(d), and amendments thereto, or any
31 substance designated in K.S.A. 65-4105(h), and amendments thereto, or an
32 analog thereof.

33 (3) If the substance involved is marijuana, as designated in K.S.A.
34 65-4105(d), and amendments thereto, violation of subsection (b) is a:

35 (A) Class B nonperson misdemeanor, except as provided in (c)(3)(B)
36 and (c)(3)(C);

37 (B) class A nonperson misdemeanor if that person has a prior
38 conviction under such subsection, under K.S.A. 65-4162, prior to its
39 repeal, under a substantially similar offense from another jurisdiction, or
40 under any city ordinance or county resolution for a substantially similar
41 offense; and

42 (C) drug severity level 5 felony if that person has two or more prior
43 convictions under such subsection, under K.S.A. 65-4162, prior to its

1 repeal, under a substantially similar offense from another jurisdiction, or
2 under any city ordinance or county resolution for a substantially similar
3 offense.

4 (d) It shall not be a defense to charges arising under this section that
5 the defendant was acting in an agency relationship on behalf of any other
6 party in a transaction involving a controlled substance or controlled
7 substance analog.

8 Sec. 5. K.S.A. 2016 Supp. 21-5708 is hereby amended to read as
9 follows: 21-5708. (a) Unlawfully obtaining a prescription-only drug is:

10 (1) Making, altering or signing of a prescription order by a person
11 other than a practitioner or a mid-level practitioner;

12 (2) distribution of a prescription order, knowing it to have been made,
13 altered or signed by a person other than a practitioner or a mid-level
14 practitioner;

15 (3) possession of a prescription order with intent to distribute it and
16 knowing it to have been made, altered or signed by a person other than a
17 practitioner or a mid-level practitioner;

18 (4) possession of a prescription-only drug knowing it to have been
19 obtained pursuant to a prescription order made, altered or signed by a
20 person other than a practitioner or a mid-level practitioner; or

21 (5) providing false information, with the intent to deceive, to a
22 practitioner or mid-level practitioner for the purpose of obtaining a
23 prescription-only drug.

24 (b) Unlawfully selling a prescription-only drug is unlawfully
25 obtaining a prescription-only drug, as defined in subsection (a), and:

26 (1) Selling the prescription-only drug so obtained;

27 (2) offering for sale the prescription-only drug so obtained; or

28 (3) possessing with intent to sell the prescription-only drug so
29 obtained.

30 (c) (1) Unlawfully obtaining a prescription-only drug is a:

31 (A) Class A nonperson misdemeanor, except as provided in
32 subsection (c)(1)(B); and

33 (B) nondrug severity level 9, nonperson felony if that person has a
34 prior conviction of under this section, K.S.A. 2010 Supp. 21-36a08, prior
35 to its transfer, or K.S.A. 21-4214, prior to its repeal.

36 (2) Unlawfully selling a prescription-only drug is a nondrug severity
37 level 6, nonperson felony.

38 (d) As used in this section:

39 (1) "Pharmacist," "practitioner," "mid-level practitioner" and
40 "prescription-only drug" shall have the meanings ascribed thereto by
41 K.S.A. 65-1626, and amendments thereto.

42 (2) "Prescription order" means an order transmitted in writing, orally,
43 telephonically or by other means of communication for a prescription-only

1 drug to be filled by a pharmacist. "Prescription order" does not mean a
2 drug dispensed pursuant to such an order. *Prescription order includes a*
3 *recommendation order issued by a physician, with the same intent, force*
4 *and effect as a prescription order, for non-intoxicating cannabinoid*
5 *medicine.*

6 (e) The provisions of this section shall not be applicable to
7 prosecutions involving prescription-only drugs which could be brought
8 under K.S.A. 2016 Supp. 21-5705 or 21-5706, and amendments thereto.

9 Sec. 6. K.S.A. 2016 Supp. 21-5709 is hereby amended to read as
10 follows: 21-5709. (a) It shall be unlawful for any person to possess
11 ephedrine, pseudoephedrine, red phosphorus, lithium metal, sodium metal,
12 iodine, anhydrous ammonia, pressurized ammonia or
13 phenylpropanolamine, or their salts, isomers or salts of isomers with an
14 intent to use the product to manufacture a controlled substance.

15 (b) *Except for drug paraphernalia used, or possessed with intent to*
16 *use, to administer non-intoxicating cannabinoid medicine pursuant to a*
17 *physician recommendation order*; it shall be unlawful for any person to use
18 or possess with intent to use any drug paraphernalia to:

19 (1) Manufacture, cultivate, plant, propagate, harvest, test, analyze or
20 distribute a controlled substance; or

21 (2) store, contain, conceal, inject, ingest, inhale or otherwise
22 introduce a controlled substance into the human body.

23 (c) It shall be unlawful for any person to use or possess with intent to
24 use anhydrous ammonia or pressurized ammonia in a container not
25 approved for that chemical by the Kansas department of agriculture.

26 (d) It shall be unlawful for any person to purchase, receive or
27 otherwise acquire at retail any compound, mixture or preparation
28 containing more than 3.6 grams of pseudoephedrine base or ephedrine
29 base in any single transaction or any compound, mixture or preparation
30 containing more than nine grams of pseudoephedrine base or ephedrine
31 base within any 30-day period.

32 (e) (1) Violation of subsection (a) is a drug severity level 3 felony;

33 (2) violation of subsection (b)(1) is a:

34 (A) Drug severity level 5 felony, except as provided in subsection (e)
35 (2)(B); and

36 (B) class A nonperson misdemeanor if the drug paraphernalia was
37 used to cultivate fewer than five marijuana plants;

38 (3) violation of subsection (b)(2) is a class A nonperson
39 misdemeanor;

40 (4) violation of subsection (c) is a drug severity level 5 felony; and

41 (5) violation of subsection (d) is a class A nonperson misdemeanor.

42 (f) For persons arrested and charged under subsection (a) or (c), bail
43 shall be at least \$50,000 cash or surety, and such person shall not be

1 released upon the person's own recognizance pursuant to K.S.A. 22-2802,
2 and amendments thereto, unless the court determines, on the record, that
3 the defendant is not likely to reoffend, the court imposes pretrial
4 supervision or the defendant agrees to participate in a licensed or certified
5 drug treatment program.

6 Sec. 7. K.S.A. 2016 Supp. 65-1626 is hereby amended to read as
7 follows: 65-1626. For the purposes of this act:

8 (a) "Administer" means the direct application of a drug, whether by
9 injection, inhalation, ingestion or any other means, to the body of a patient
10 or research subject by:

11 (1) A practitioner or pursuant to the lawful direction of a practitioner;

12 (2) the patient or research subject at the direction and in the presence
13 of the practitioner; or

14 (3) a pharmacist as authorized in K.S.A. 65-1635a, and amendments
15 thereto.

16 (b) "Agent" means an authorized person who acts on behalf of or at
17 the direction of a manufacturer, distributor or dispenser but shall not
18 include a common carrier, public warehouseman or employee of the carrier
19 or warehouseman when acting in the usual and lawful course of the
20 carrier's or warehouseman's business.

21 (c) "Application service provider" means an entity that sells
22 electronic prescription or pharmacy prescription applications as a hosted
23 service where the entity controls access to the application and maintains
24 the software and records on its server.

25 (d) "Authorized distributor of record" means a wholesale distributor
26 with whom a manufacturer has established an ongoing relationship to
27 distribute the manufacturer's prescription drug. An ongoing relationship is
28 deemed to exist between such wholesale distributor and a manufacturer
29 when the wholesale distributor, including any affiliated group of the
30 wholesale distributor, as defined in section 1504 of the internal revenue
31 code, complies with any one of the following: (1) The wholesale
32 distributor has a written agreement currently in effect with the
33 manufacturer evidencing such ongoing relationship; and (2) the wholesale
34 distributor is listed on the manufacturer's current list of authorized
35 distributors of record, which is updated by the manufacturer on no less
36 than a monthly basis.

37 (e) "Board" means the state board of pharmacy created by K.S.A. 74-
38 1603, and amendments thereto.

39 (f) "Brand exchange" means the dispensing of a different drug
40 product of the same dosage form and strength and of the same generic
41 name as the brand name drug product prescribed.

42 (g) "Brand name" means the registered trademark name given to a
43 drug product by its manufacturer, labeler or distributor.

1 (h) "Chain pharmacy warehouse" means a permanent physical
2 location for drugs or devices, or both, that acts as a central warehouse and
3 performs intracompany sales or transfers of prescription drugs or devices
4 to chain pharmacies that have the same ownership or control. Chain
5 pharmacy warehouses must be registered as wholesale distributors.

6 (i) "Co-licensee" means a pharmaceutical manufacturer that has
7 entered into an agreement with another pharmaceutical manufacturer to
8 engage in a business activity or occupation related to the manufacture or
9 distribution of a prescription drug and the national drug code on the drug
10 product label shall be used to determine the identity of the drug
11 manufacturer.

12 (j) "DEA" means the U.S. department of justice, drug enforcement
13 administration.

14 (k) "Deliver" or "delivery" means the actual, constructive or
15 attempted transfer from one person to another of any drug whether or not
16 an agency relationship exists.

17 (l) "Direct supervision" means the process by which the responsible
18 pharmacist shall observe and direct the activities of a pharmacy student or
19 pharmacy technician to a sufficient degree to assure that all such activities
20 are performed accurately, safely and without risk or harm to patients, and
21 complete the final check before dispensing.

22 (m) "Dispense" means to deliver prescription medication to the
23 ultimate user or research subject by or pursuant to the lawful order of a
24 practitioner or pursuant to the prescription of a mid-level practitioner.

25 (n) "Dispenser" means a practitioner or pharmacist who dispenses
26 prescription medication, or a physician assistant who has authority to
27 dispense prescription-only drugs in accordance with K.S.A. 65-28a08(b),
28 and amendments thereto.

29 (o) "Distribute" means to deliver, other than by administering or
30 dispensing, any drug.

31 (p) "Distributor" means a person who distributes a drug.

32 (q) "Drop shipment" means the sale, by a manufacturer, that
33 manufacturer's co-licensee, that manufacturer's third party logistics
34 provider, or that manufacturer's exclusive distributor, of the manufacturer's
35 prescription drug, to a wholesale distributor whereby the wholesale
36 distributor takes title but not possession of such prescription drug and the
37 wholesale distributor invoices the pharmacy, the chain pharmacy
38 warehouse, or other designated person authorized by law to dispense or
39 administer such prescription drug, and the pharmacy, the chain pharmacy
40 warehouse, or other designated person authorized by law to dispense or
41 administer such prescription drug receives delivery of the prescription
42 drug directly from the manufacturer, that manufacturer's co-licensee, that
43 manufacturer's third party logistics provider, or that manufacturer's

1 exclusive distributor, of such prescription drug. Drop shipment shall be
2 part of the "normal distribution channel."

3 (r) "Drug" means: (1) Articles recognized in the official United States
4 pharmacopoeia, or other such official compendiums of the United States,
5 or official national formulary, or any supplement of any of them; (2)
6 articles intended for use in the diagnosis, cure, mitigation, treatment or
7 prevention of disease in human or other animals; (3) articles, other than
8 food, intended to affect the structure or any function of the body of human
9 or other animals; and (4) articles intended for use as a component of any
10 articles specified in paragraph (1), (2) or (3); but does not include devices
11 or their components, parts or accessories, except that the term "drug" shall
12 not include amygdalin (laetrile) or any livestock remedy, if such livestock
13 remedy had been registered in accordance with the provisions of article 5
14 of chapter 47 of the Kansas Statutes Annotated, prior to its repeal.

15 (s) "Durable medical equipment" means technologically sophisticated
16 medical devices that may be used in a residence, including the following:
17 (1) Oxygen and oxygen delivery system; (2) ventilators; (3) respiratory
18 disease management devices; (4) continuous positive airway pressure
19 (CPAP) devices; (5) electronic and computerized wheelchairs and seating
20 systems; (6) apnea monitors; (7) transcutaneous electrical nerve stimulator
21 (TENS) units; (8) low air loss cutaneous pressure management devices; (9)
22 sequential compression devices; (10) feeding pumps; (11) home
23 phototherapy devices; (12) infusion delivery devices; (13) distribution of
24 medical gases to end users for human consumption; (14) hospital beds;
25 (15) nebulizers; or (16) other similar equipment determined by the board
26 in rules and regulations adopted by the board.

27 (t) "Electronic prescription" means an electronically prepared
28 prescription that is authorized and transmitted from the prescriber to the
29 pharmacy by means of electronic transmission.

30 (u) "Electronic prescription application" means software that is used
31 to create electronic prescriptions and that is intended to be installed on the
32 prescriber's computers and servers where access and records are controlled
33 by the prescriber.

34 (v) "Electronic signature" means a confidential personalized digital
35 key, code, number or other method for secure electronic data transmissions
36 which identifies a particular person as the source of the message,
37 authenticates the signatory of the message and indicates the person's
38 approval of the information contained in the transmission.

39 (w) "Electronic transmission" means the transmission of an electronic
40 prescription, formatted as an electronic data file, from a prescriber's
41 electronic prescription application to a pharmacy's computer, where the
42 data file is imported into the pharmacy prescription application.

43 (x) "Electronically prepared prescription" means a prescription that is

1 generated using an electronic prescription application.

2 (y) "Exclusive distributor" means any entity that: (1) Contracts with a
3 manufacturer to provide or coordinate warehousing, wholesale distribution
4 or other services on behalf of a manufacturer and who takes title to that
5 manufacturer's prescription drug, but who does not have general
6 responsibility to direct the sale or disposition of the manufacturer's
7 prescription drug; (2) is registered as a wholesale distributor under the
8 pharmacy act of the state of Kansas; and (3) to be considered part of the
9 normal distribution channel, must be an authorized distributor of record.

10 (z) "Facsimile transmission" or "fax transmission" means the
11 transmission of a digital image of a prescription from the prescriber or the
12 prescriber's agent to the pharmacy. "Facsimile transmission" includes, but
13 is not limited to, transmission of a written prescription between the
14 prescriber's fax machine and the pharmacy's fax machine; transmission of
15 an electronically prepared prescription from the prescriber's electronic
16 prescription application to the pharmacy's fax machine, computer or
17 printer; or transmission of an electronically prepared prescription from the
18 prescriber's fax machine to the pharmacy's fax machine, computer or
19 printer.

20 (aa) "Generic name" means the established chemical name or official
21 name of a drug or drug product.

22 (bb) (1) "Institutional drug room" means any location where
23 prescription-only drugs are stored and from which prescription-only drugs
24 are administered or dispensed and which is maintained or operated for the
25 purpose of providing the drug needs of:

26 (A) Inmates of a jail or correctional institution or facility;

27 (B) residents of a juvenile detention facility, as defined by the revised
28 Kansas code for care of children and the revised Kansas juvenile justice
29 code;

30 (C) students of a public or private university or college, a community
31 college or any other institution of higher learning which is located in
32 Kansas;

33 (D) employees of a business or other employer; or

34 (E) persons receiving inpatient hospice services.

35 (2) "Institutional drug room" does not include:

36 (A) Any registered pharmacy;

37 (B) any office of a practitioner; or

38 (C) a location where no prescription-only drugs are dispensed and no
39 prescription-only drugs other than individual prescriptions are stored or
40 administered.

41 (cc) "Intermediary" means any technology system that receives and
42 transmits an electronic prescription between the prescriber and the
43 pharmacy.

1 (dd) "Intracompany transaction" means any transaction or transfer
2 between any division, subsidiary, parent or affiliated or related company
3 under common ownership or control of a corporate entity, or any
4 transaction or transfer between co-licensees of a co-licensed product.

5 (ee) "Medical care facility" shall have the meaning provided in
6 K.S.A. 65-425, and amendments thereto, except that the term shall also
7 include facilities licensed under the provisions of K.S.A. 75-3307b, and
8 amendments thereto, except community mental health centers and
9 facilities for people with intellectual disability.

10 (ff) "Manufacture" means the production, preparation, propagation,
11 compounding, conversion or processing of a drug either directly or
12 indirectly by extraction from substances of natural origin, independently
13 by means of chemical synthesis or by a combination of extraction and
14 chemical synthesis and includes any packaging or repackaging of the drug
15 or labeling or relabeling of its container, except that this term shall not
16 include the preparation or compounding of a drug by an individual for the
17 individual's own use or the preparation, compounding, packaging or
18 labeling of a drug by:

19 (1) A practitioner or a practitioner's authorized agent incident to such
20 practitioner's administering or dispensing of a drug in the course of the
21 practitioner's professional practice;

22 (2) a practitioner, by a practitioner's authorized agent or under a
23 practitioner's supervision for the purpose of, or as an incident to, research,
24 teaching or chemical analysis and not for sale; or

25 (3) a pharmacist or the pharmacist's authorized agent acting under the
26 direct supervision of the pharmacist for the purpose of, or incident to, the
27 dispensing of a drug by the pharmacist.

28 (gg) "Manufacturer" means a person licensed or approved by the
29 FDA to engage in the manufacture of drugs and devices.

30 (hh) "Mid-level practitioner" means a certified nurse-midwife
31 engaging in the independent practice of midwifery under the independent
32 practice of midwifery act, an advanced practice registered nurse issued a
33 license pursuant to K.S.A. 65-1131, and amendments thereto, who has
34 authority to prescribe drugs pursuant to a written protocol with a
35 responsible physician under K.S.A. 65-1130, and amendments thereto, or a
36 physician assistant licensed pursuant to the physician assistant licensure
37 act who has authority to prescribe drugs pursuant to a written agreement
38 with a supervising physician under K.S.A. 65-28a08, and amendments
39 thereto.

40 (ii) "Normal distribution channel" means a chain of custody for a
41 prescription-only drug that goes from a manufacturer of the prescription-
42 only drug, from that manufacturer to that manufacturer's co-licensed
43 partner, from that manufacturer to that manufacturer's third-party logistics

1 provider or from that manufacturer to that manufacturer's exclusive
2 distributor, directly or by drop shipment, to:

3 (1) A pharmacy to a patient or to other designated persons authorized
4 by law to dispense or administer such drug to a patient;

5 (2) a wholesale distributor to a pharmacy to a patient or other
6 designated persons authorized by law to dispense or administer such drug
7 to a patient;

8 (3) a wholesale distributor to a chain pharmacy warehouse to that
9 chain pharmacy warehouse's intracompany pharmacy to a patient or other
10 designated persons authorized by law to dispense or administer such drug
11 to a patient; or

12 (4) a chain pharmacy warehouse to the chain pharmacy warehouse's
13 intracompany pharmacy to a patient or other designated persons authorized
14 by law to dispense or administer such drug to a patient.

15 (jj) "Person" means individual, corporation, government,
16 governmental subdivision or agency, partnership, association or any other
17 legal entity.

18 (kk) "Pharmacist" means any natural person licensed under this act to
19 practice pharmacy.

20 (ll) "Pharmacist-in-charge" means the pharmacist who is responsible
21 to the board for a registered establishment's compliance with the laws and
22 regulations of this state pertaining to the practice of pharmacy,
23 manufacturing of drugs and the distribution of drugs. The pharmacist-in-
24 charge shall supervise such establishment on a full-time or a part-time
25 basis and perform such other duties relating to supervision of a registered
26 establishment as may be prescribed by the board by rules and regulations.
27 Nothing in this definition shall relieve other pharmacists or persons from
28 their responsibility to comply with state and federal laws and regulations.

29 (mm) "Pharmacist intern" means: (1) A student currently enrolled in
30 an accredited pharmacy program; (2) a graduate of an accredited pharmacy
31 program serving an internship; or (3) a graduate of a pharmacy program
32 located outside of the United States which is not accredited and who has
33 successfully passed equivalency examinations approved by the board.

34 (nn) "Pharmacy," "drugstore" or "apothecary" means premises,
35 laboratory, area or other place: (1) Where drugs are offered for sale where
36 the profession of pharmacy is practiced and where prescriptions are
37 compounded and dispensed; or (2) which has displayed upon it or within it
38 the words "pharmacist," "pharmaceutical chemist," "pharmacy,"
39 "apothecary," "drugstore," "druggist," "drugs," "drug sundries" or any of
40 these words or combinations of these words or words of similar import
41 either in English or any sign containing any of these words; or (3) where
42 the characteristic symbols of pharmacy or the characteristic prescription
43 sign "Rx" may be exhibited. As used in this subsection, premises refers

1 only to the portion of any building or structure leased, used or controlled
2 by the licensee in the conduct of the business registered by the board at the
3 address for which the registration was issued.

4 (oo) "Pharmacy prescription application" means software that is used
5 to process prescription information, is installed on a pharmacy's computers
6 or servers, and is controlled by the pharmacy.

7 (pp) "Pharmacy technician" means an individual who, under the
8 direct supervision and control of a pharmacist, may perform packaging,
9 manipulative, repetitive or other nondiscretionary tasks related to the
10 processing of a prescription or medication order and who assists the
11 pharmacist in the performance of pharmacy related duties, but who does
12 not perform duties restricted to a pharmacist.

13 (qq) "Practitioner" means a person licensed to practice medicine and
14 surgery, dentist, podiatrist, veterinarian, optometrist or scientific
15 investigator or other person authorized by law to use a prescription-only
16 drug in teaching or chemical analysis or to conduct research with respect
17 to a prescription-only drug.

18 (rr) "Preceptor" means a licensed pharmacist who possesses at least
19 two years' experience as a pharmacist and who supervises students
20 obtaining the pharmaceutical experience required by law as a condition to
21 taking the examination for licensure as a pharmacist.

22 (ss) "Prescriber" means a practitioner or a mid-level practitioner.

23 (tt) "Prescription" or "prescription order" means: (1) An order to be
24 filled by a pharmacist for prescription medication issued and signed by a
25 prescriber in the authorized course of such prescriber's professional
26 practice; or (2) an order transmitted to a pharmacist through word of
27 mouth, note, telephone or other means of communication directed by such
28 prescriber, regardless of whether the communication is oral, electronic,
29 facsimile or in printed form. *"Prescription order" includes a*
30 *recommendation order issued by a physician, with the same intent, force*
31 *and effect as a prescription order, for non-intoxicating cannabinoid*
32 *medicine.*

33 (uu) "Prescription medication" means any drug, including label and
34 container according to context, which is dispensed pursuant to a
35 prescription order.

36 (vv) "Prescription-only drug" means any drug whether intended for
37 use by human or animal, required by federal or state law, including 21
38 U.S.C. § 353, to be dispensed only pursuant to a written or oral
39 prescription or order of a practitioner or is restricted to use by practitioners
40 only.

41 (ww) "Probation" means the practice or operation under a temporary
42 license, registration or permit or a conditional license, registration or
43 permit of a business or profession for which a license, registration or

1 permit is granted by the board under the provisions of the pharmacy act of
2 the state of Kansas requiring certain actions to be accomplished or certain
3 actions not to occur before a regular license, registration or permit is
4 issued.

5 (xx) "Professional incompetency" means:

6 (1) One or more instances involving failure to adhere to the
7 applicable standard of pharmaceutical care to a degree which constitutes
8 gross negligence, as determined by the board;

9 (2) repeated instances involving failure to adhere to the applicable
10 standard of pharmaceutical care to a degree which constitutes ordinary
11 negligence, as determined by the board; or

12 (3) a pattern of pharmacy practice or other behavior which
13 demonstrates a manifest incapacity or incompetence to practice pharmacy.

14 (yy) "Readily retrievable" means that records kept by automatic data
15 processing applications or other electronic or mechanized record-keeping
16 systems can be separated out from all other records within a reasonable
17 time not to exceed 48 hours of a request from the board or other authorized
18 agent or that hard-copy records are kept on which certain items are
19 asterisked, redlined or in some other manner visually identifiable apart
20 from other items appearing on the records.

21 (zz) "Retail dealer" means a person selling at retail nonprescription
22 drugs which are prepackaged, fully prepared by the manufacturer or
23 distributor for use by the consumer and labeled in accordance with the
24 requirements of the state and federal food, drug and cosmetic acts. Such
25 nonprescription drugs shall not include: (1) A controlled substance; (2) a
26 prescription-only drug; or (3) a drug intended for human use by
27 hypodermic injection.

28 (aaa) "Secretary" means the executive secretary of the board.

29 (bbb) "Third party logistics provider" means an entity that: (1)
30 Provides or coordinates warehousing, distribution or other services on
31 behalf of a manufacturer, but does not take title to the prescription drug or
32 have general responsibility to direct the prescription drug's sale or
33 disposition; (2) is registered as a wholesale distributor under the pharmacy
34 act of the state of Kansas; and (3) to be considered part of the normal
35 distribution channel, must also be an authorized distributor of record.

36 (ccc) "Unprofessional conduct" means:

37 (1) Fraud in securing a registration or permit;

38 (2) intentional adulteration or mislabeling of any drug, medicine,
39 chemical or poison;

40 (3) causing any drug, medicine, chemical or poison to be adulterated
41 or mislabeled, knowing the same to be adulterated or mislabeled;

42 (4) intentionally falsifying or altering records or prescriptions;

43 (5) unlawful possession of drugs and unlawful diversion of drugs to

1 others;

2 (6) willful betrayal of confidential information under K.S.A. 65-1654,
3 and amendments thereto;

4 (7) conduct likely to deceive, defraud or harm the public;

5 (8) making a false or misleading statement regarding the licensee's
6 professional practice or the efficacy or value of a drug;

7 (9) commission of any act of sexual abuse, misconduct or
8 exploitation related to the licensee's professional practice; or

9 (10) performing unnecessary tests, examinations or services which
10 have no legitimate pharmaceutical purpose.

11 (ddd) "Vaccination protocol" means a written protocol, agreed to by a
12 pharmacist and a person licensed to practice medicine and surgery by the
13 state board of healing arts, which establishes procedures and
14 recordkeeping and reporting requirements for administering a vaccine by
15 the pharmacist for a period of time specified therein, not to exceed two
16 years.

17 (eee) "Valid prescription order" means a prescription that is issued for
18 a legitimate medical purpose by an individual prescriber licensed by law to
19 administer and prescribe drugs and acting in the usual course of such
20 prescriber's professional practice. A prescription issued solely on the basis
21 of an internet-based questionnaire or consultation without an appropriate
22 prescriber-patient relationship is not a valid prescription order.

23 (fff) "Veterinary medical teaching hospital pharmacy" means any
24 location where prescription-only drugs are stored as part of an accredited
25 college of veterinary medicine and from which prescription-only drugs are
26 distributed for use in treatment of or administration to a nonhuman.

27 (ggg) "Wholesale distributor" means any person engaged in
28 wholesale distribution of prescription drugs or devices in or into the state,
29 including, but not limited to, manufacturers, repackagers, own-label
30 distributors, private-label distributors, jobbers, brokers, warehouses,
31 including manufacturers' and distributors' warehouses, co-licensees,
32 exclusive distributors, third party logistics providers, chain pharmacy
33 warehouses that conduct wholesale distributions, and wholesale drug
34 warehouses, independent wholesale drug traders and retail pharmacies that
35 conduct wholesale distributions. Wholesale distributor shall not include
36 persons engaged in the sale of durable medical equipment to consumers or
37 patients.

38 (hhh) "Wholesale distribution" means the distribution of prescription
39 drugs or devices by wholesale distributors to persons other than consumers
40 or patients, and includes the transfer of prescription drugs by a pharmacy
41 to another pharmacy if the total number of units of transferred drugs
42 during a twelve-month period does not exceed 5% of the total number of
43 all units dispensed by the pharmacy during the immediately preceding

1 twelve-month period. Wholesale distribution does not include:

- 2 (1) The sale, purchase or trade of a prescription drug or device, an
3 offer to sell, purchase or trade a prescription drug or device or the
4 dispensing of a prescription drug or device pursuant to a prescription;
- 5 (2) the sale, purchase or trade of a prescription drug or device or an
6 offer to sell, purchase or trade a prescription drug or device for emergency
7 medical reasons;
- 8 (3) intracompany transactions, as defined in this section, unless in
9 violation of own use provisions;
- 10 (4) the sale, purchase or trade of a prescription drug or device or an
11 offer to sell, purchase or trade a prescription drug or device among
12 hospitals, chain pharmacy warehouses, pharmacies or other health care
13 entities that are under common control;
- 14 (5) the sale, purchase or trade of a prescription drug or device or the
15 offer to sell, purchase or trade a prescription drug or device by a charitable
16 organization described in 503(c)(3) of the internal revenue code of 1954 to
17 a nonprofit affiliate of the organization to the extent otherwise permitted
18 by law;
- 19 (6) the purchase or other acquisition by a hospital or other similar
20 health care entity that is a member of a group purchasing organization of a
21 prescription drug or device for its own use from the group purchasing
22 organization or from other hospitals or similar health care entities that are
23 members of these organizations;
- 24 (7) the transfer of prescription drugs or devices between pharmacies
25 pursuant to a centralized prescription processing agreement;
- 26 (8) the sale, purchase or trade of blood and blood components
27 intended for transfusion;
- 28 (9) the return of recalled, expired, damaged or otherwise non-salable
29 prescription drugs, when conducted by a hospital, health care entity,
30 pharmacy, chain pharmacy warehouse or charitable institution in
31 accordance with the board's rules and regulations;
- 32 (10) the sale, transfer, merger or consolidation of all or part of the
33 business of a retail pharmacy or pharmacies from or with another retail
34 pharmacy or pharmacies, whether accomplished as a purchase and sale of
35 stock or business assets, in accordance with the board's rules and
36 regulations;
- 37 (11) the distribution of drug samples by manufacturers' and
38 authorized distributors' representatives;
- 39 (12) the sale of minimal quantities of drugs by retail pharmacies to
40 licensed practitioners for office use; or
- 41 (13) the sale or transfer from a retail pharmacy or chain pharmacy
42 warehouse of expired, damaged, returned or recalled prescription drugs to
43 the original manufacturer, originating wholesale distributor or to a third

1 party returns processor in accordance with the board's rules and
2 regulations.

3 Sec. 8. K.S.A. 2016 Supp. 65-4123 is hereby amended to read as
4 follows: 65-4123. (a) Except as otherwise provided in K.S.A. 65-4117, and
5 amendments thereto, or in this subsection (a), no schedule I controlled
6 substance may be dispensed. The board by rules and regulations may
7 designate in accordance with the provisions of this subsection (a) a
8 schedule I controlled substance as a schedule I designated prescription
9 substance. *Non-intoxicating cannabinoid medicine may be dispensed*
10 *pursuant to a physician recommendation order.*

11 (b) Except when dispensed by a practitioner, other than a pharmacy,
12 to an ultimate user, no controlled substance in schedule II may be
13 dispensed without the written or electronic prescription of a prescriber. In
14 emergency situations, as defined by rules and regulations of the board,
15 schedule II drugs may be dispensed upon oral prescription of a prescriber
16 reduced promptly to writing or transmitted electronically and filed by the
17 pharmacy. No prescription for a schedule II substance may be refilled.

18 (c) Except when dispensed by a practitioner, other than a pharmacy,
19 to an ultimate user, a controlled substance included in schedule III, IV or V
20 which is a prescription drug shall not be dispensed without either a paper
21 prescription manually signed by a prescriber, a facsimile of a manually
22 signed paper prescription transmitted by the prescriber or the prescriber's
23 agent to the pharmacy, an electronic prescription that has been digitally
24 signed by a prescriber with a digital certificate, or an oral prescription
25 made by an individual prescriber and promptly reduced to writing. The
26 prescription shall not be filled or refilled more than six months after the
27 date thereof or be refilled more than five times.

28 (d) A controlled substance shall not be distributed or dispensed
29 except by a valid prescription order as defined in K.S.A. 65-1626, and
30 amendments thereto, *or a valid recommendation order issued by a*
31 *physician, with the same intent, force and effect as a prescription order;*
32 *for non-intoxicating cannabinoid medicine.* Electronic prescriptions shall
33 be retained electronically for five years from the date of their creation or
34 receipt. The records must be readily retrievable from all other records and
35 easily rendered into a format a person can read. Paper, oral and facsimile
36 prescriptions shall be maintained as a hard copy for five years at the
37 registered location.

38 Sec. 9. K.S.A. 2016 Supp. 21-5706, 21-5708, 21-5709, 65-1626 and
39 65-4123 are hereby repealed.

40 Sec. 10. This act shall take effect and be in force from and after its
41 publication in the statute book.